Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS) (COPP-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03917589
Recruitment Status : Not yet recruiting
First Posted : April 17, 2019
Last Update Posted : May 9, 2019
Sponsor:
Information provided by (Responsible Party):
Rennes University Hospital

Brief Summary:

Multiple Sclerosis (MS) is most prevalent among women of childbearing age. The post-partum (PP) period is a critical phase in MS patients, during which a recrudescence of disease activity is expected. Different strategies have been assessed in the prevention of post-partum relapse. High dose methylprednisolone was evaluated in a case control study with historical controls but the positive results have not been confirmed.

In this study, the main objective will be to compare the risk of relapse in the 6 months PP period between patients treated systematically by high dose methylprednisolone after delivery compared to patients who didn't receive a systematic treatment.

The second objective will be focused on the comparison of the disease activity and disability progression in patients who have resumed early a Disease Modifying Drug (DMD) after delivery vs patients who haven't.


Condition or disease
Multiple Sclerosis

Detailed Description:
Even if two small case control studies underlined the positive effect of high dose methylprednisolone on the relapse risk in the PP period in MS, these data have to be confirmed by a larger study. The impact of such a strategy remains also uncertain concerning the risk of long term disability. In this project, the investigators will also analyze the influence of the delay of DMD reintroduction after delivery on the relapse risk but also on the risk of disability. The results will have an important role in the therapeutic management of the post-partum period in MS patients.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 242 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS
Estimated Study Start Date : May 15, 2019
Estimated Primary Completion Date : May 15, 2021
Estimated Study Completion Date : May 15, 2021

Resource links provided by the National Library of Medicine


Group/Cohort
Patients with corticosteroids
Patients who have systematically been treated by high-dose corticosteroids after the delivery
Patients without corticosteroids
Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.



Primary Outcome Measures :
  1. Difference of the proportion of patients with >= 1 relapse between the two groups [ Time Frame: 6 months ]
    proportion of patients with >= 1 relapse during the six-month period after delivery between the patients who have systematically been treated by high-dose corticosteroids after the delivery; and patients who haven't been systematically treated by high-dose corticosteroids.


Secondary Outcome Measures :
  1. Difference of the proportion of patients with >= 1 relapse [ Time Frame: 6 months ]
    proportion of patients with >= 1 relapse during the six-month period after delivery between patients who have resumed a DMD early after the delivery (during the first two months) compared to a delayed reintroduction, or an absence of reintroduction

  2. Difference of the annualized relapse rate [ Time Frame: 6 months ]
    Number of the annualized relapse rate after the delivery between corticosteroids or not and between early DMD vs delayed DMD

  3. Difference of the annualized relapse rate [ Time Frame: 1 year ]
    Number of the annualized relapse rate after the delivery between corticosteroids or not and between early DMD vs delayed DMD

  4. Difference of the annualized relapse rate [ Time Frame: two years ]
    Number of the annualized relapse rate after the delivery between corticosteroids or not and between early DMD vs delayed DMD

  5. Difference of the time to first relapse [ Time Frame: Date of delivery ]
    Time to first relapse after delivery between corticosteroids or not and between early DMD vs delayed DMD

  6. Difference of the disability progression [ Time Frame: 6 months ]
    Score of Expanded Disability Status Scale (EDSS) (from 0=no disability, to 10= Death / No sub scales) between corticosteroids or not and between early DMD vs delayed DMD

  7. Difference of the disability progression [ Time Frame: 1 year ]
    Score of Expanded Disability Status Scale (EDSS) (from 0=no disability, to 10= Death / No sub scales) between corticosteroids or not and between early DMD vs delayed DMD

  8. Difference of the disability progression [ Time Frame: 2 years ]
    Score of Expanded Disability Status Scale (EDSS) (from 0=no disability, to 10= Death / No sub scales) between corticosteroids or not and between early DMD vs delayed DMD

  9. Difference of percentage of with Gadolinium enhancing lesions [ Time Frame: 6 months ]
    Difference of percentage of with Gadolinium enhancing lesions during the 6-month period after the delivery between corticosteroids or not and between early DMD vs delayed DMD

  10. Difference of the number of Gadolinium enhancing lesions [ Time Frame: 6 months ]
    compare the number of Gadolinium enhancing lesions during the 6-month period after the delivery between corticosteroids or not and between early DMD vs delayed DMD



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 49 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Study of Preventive use of COrticosteroids during the Post-Partum
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
relapsing MS patients with at least one full pregnancy with live birth between 01/2007 and 01/2017 after the beginning of the MS diagnosis
Criteria

Inclusion Criteria:

  • Relapsing MS patients according to MacDonald criteria 2010
  • Age between 15 and 49 years old at the pregnancy
  • Age between 18 and 51 years old when filling the questionnaire of the study
  • At least one full pregnancy with live birth after the beginning of the MS diagnosis
  • At least one neurological visit during the 12 months period after the delivery
  • At least one neurological visit per year in the 12 months preceding the pregnancy
  • Pregnancy must occur between 01/2007 and 01/2017 In case of several pregnancies per woman, only the first one occurring in the period will be analyzed
  • Having received information on the protocol and not having expressed opposition to participating in the study.

Exclusion Criteria:

  • Patients who have received Immunoglobulines or plasma exchanges after the delivery in prevention of a relapse
  • Patients presenting a SPMS or PPMS form at the beginning of pregnancy
  • Protected persons referred to in Articles L. 1121-6 to L. 1121-9 of the code of public health (eg minors, persons deprived of liberty, ..) except nursing mothers postpartum.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03917589


Contacts
Layout table for location contacts
Contact: Laure MICHEL, Dr 2 99 28 43 21 ext +33 laure.michel@chu-rennes.fr

Locations
Layout table for location information
France
Hôpital LAENNEC Not yet recruiting
Saint Herblain, Nantes, France, 44800
Contact: David LAPLAUD, Pr         
CHU Lyon Not yet recruiting
Lyon, France
Contact: Sandra VUKUSIC, Pr         
Hôpital Pasteur 2 - CHU Nice Not yet recruiting
Nice, France, 06000
Contact: Christine LEBRUN-FRENAY, Pr         
CHU Rennes Not yet recruiting
Rennes, France, 35033
Contact: Laure MICHEL, Dr         
CHU Strasbourg Not yet recruiting
Strasbourg, France, 67098
Contact: Jérôme DE SEZE, Pr         
Sponsors and Collaborators
Rennes University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Laure MICHEL, Dr CHU Rennes

Layout table for additonal information
Responsible Party: Rennes University Hospital
ClinicalTrials.gov Identifier: NCT03917589     History of Changes
Other Study ID Numbers: 35RC18_9844_COPP-MS
First Posted: April 17, 2019    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rennes University Hospital:
post-partum
corticosteroids
relapse
disease modifying drugs (DMD)
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases